271 related articles for article (PubMed ID: 28949012)
21. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
22. Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study.
Tehlirian C; Peeva E; Kieras E; Scaramozza M; Roberts ES; Singh RSP; Pradhan V; Banerjee A; Garcet S; Xi L; Gale JD; Vincent MS; Krueger J
Lancet Rheumatol; 2021 Mar; 3(3):e204-e213. PubMed ID: 38279383
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
Menter A; Papp KA; Tan H; Tyring S; Wolk R; Buonanno M
J Drugs Dermatol; 2014 Mar; 13(3):252-6. PubMed ID: 24595567
[TBL] [Abstract][Full Text] [Related]
24. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Warren RB; Mrowietz U; von Kiedrowski R; Niesmann J; Wilsmann-Theis D; Ghoreschi K; Zschocke I; Falk TM; Blödorn-Schlicht N; Reich K
Lancet; 2017 Feb; 389(10068):528-537. PubMed ID: 28012564
[TBL] [Abstract][Full Text] [Related]
25. Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial.
David M; Gospodinov DK; Gheorghe N; Mateev GS; Rusinova MV; Hristakieva E; Solovastru LG; Patel RV; Giurcaneanu C; Hitova MC; Purcaru AI; Horia B; Tsingov II; Yankova RK; Kadurina MI; Ramon M; Rotaru M; Simionescu O; Benea V; Demerdjieva ZV; Cosgarea MR; Morariu HS; Michael Z; Cristodor P; Nica C; Silverman MH; Bristol DR; Harpaz Z; Farbstein M; Cohen S; Fishman P
J Drugs Dermatol; 2016 Aug; 15(8):931-8. PubMed ID: 27537992
[TBL] [Abstract][Full Text] [Related]
26. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
Page KM; Suarez-Farinas M; Suprun M; Zhang W; Garcet S; Fuentes-Duculan J; Li X; Scaramozza M; Kieras E; Banfield C; Clark JD; Fensome A; Krueger JG; Peeva E
J Invest Dermatol; 2020 Aug; 140(8):1546-1555.e4. PubMed ID: 31972249
[TBL] [Abstract][Full Text] [Related]
27. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.
Papp K; Pariser D; Catlin M; Wierz G; Ball G; Akinlade B; Zeiher B; Krueger JG
Br J Dermatol; 2015 Sep; 173(3):767-76. PubMed ID: 25704750
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study.
Zhang J; Tsai TF; Lee MG; Zheng M; Wang G; Jin H; Gu J; Li R; Liu Q; Chen J; Tu C; Qi C; Zhu H; Ports WC; Crook T
J Dermatol Sci; 2017 Oct; 88(1):36-45. PubMed ID: 28558978
[TBL] [Abstract][Full Text] [Related]
29. Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.
Strober BE; Gottlieb AB; van de Kerkhof PCM; Puig L; Bachelez H; Chouela E; Imafuku S; Thaçi D; Tan H; Valdez H; Gupta P; Kaur M; Frajzyngier V; Wolk R
Br J Dermatol; 2019 Jan; 180(1):67-75. PubMed ID: 30188571
[TBL] [Abstract][Full Text] [Related]
30. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM
Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
Paul C; Cather J; Gooderham M; Poulin Y; Mrowietz U; Ferrandiz C; Crowley J; Hu C; Stevens RM; Shah K; Day RM; Girolomoni G; Gottlieb AB
Br J Dermatol; 2015 Dec; 173(6):1387-99. PubMed ID: 26357944
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm
Mrowietz U; Szepietowski JC; Loewe R; van de Kerkhof P; Lamarca R; Ocker WG; Tebbs VM; Pau-Charles I
Br J Dermatol; 2017 Mar; 176(3):615-623. PubMed ID: 27515097
[TBL] [Abstract][Full Text] [Related]
34. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
Merola JF; Elewski B; Tatulych S; Lan S; Tallman A; Kaur M
J Am Acad Dermatol; 2017 Jul; 77(1):79-87.e1. PubMed ID: 28396102
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis.
Bissonnette R; Luchi M; Fidelus-Gort R; Jackson S; Zhang H; Flores R; Newton R; Scherle P; Yeleswaram S; Chen X; Menter A
J Dermatolog Treat; 2016 Aug; 27(4):332-8. PubMed ID: 26769332
[TBL] [Abstract][Full Text] [Related]
38. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
[TBL] [Abstract][Full Text] [Related]
39. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
Guttman-Yassky E; Silverberg JI; Nemoto O; Forman SB; Wilke A; Prescilla R; de la Peña A; Nunes FP; Janes J; Gamalo M; Donley D; Paik J; DeLozier AM; Nickoloff BJ; Simpson EL
J Am Acad Dermatol; 2019 Apr; 80(4):913-921.e9. PubMed ID: 29410014
[TBL] [Abstract][Full Text] [Related]
40. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.
Gottlieb AB; Griffiths CE; Ho VC; Lahfa M; Mrowietz U; Murrell DF; Ortonne JP; Todd G; Cherill R; Marks I; Emady-Azar S; Paul CF;
Br J Dermatol; 2005 Jun; 152(6):1219-27. PubMed ID: 15948985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
